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INVITED REVIEW
Deep venous thrombosis (DVT) has been esti-
mated to affect more than 250,000 patients per
year.1,2 It has also been estimated that DVT and pul-
monary embolism (PE) together are associated with
300,000 to 600,000 hospitalizations and as many as
50,000 deaths yearly, although other estimates sug-
gest an even higher yearly death rate.3 DVT is
responsible for an increased mortality rate in elderly
persons, and the cost of treatment can be estimated
to be between $1.2 and $2.4 billion per year.4 Thus
venous thromboembolism remains a significant
problem today. In this article, the diagnosis of DVT
and PE will not be addressed, except to say that
venous duplex ultrasound imaging has become the
gold standard for DVT, although ventilation/perfu-
sion scanning and pulmonary arteriography are the
mainstays for the diagnosis of PE with newer modal-
ities of spiral computed tomography scanning and
magnetic resonance venography presently undergo-
ing evaluation. This article will address current treat-
ment alternatives. Modalities to be discussed include
unfractionated heparin, low–molecular weight
heparin, thrombolysis, venous thrombectomy, inferi-
or vena caval interruption, pulmonary embolectomy,
and alternative anticoagulants.
UNFRACTIONATED HEPARIN AND ORAL
ANTICOAGULATION
Treatment for DVT and PE historically involves
anticoagulation, intravenous unfractionated heparin
initially followed by long-term oral anticoagulation.
Recently, the acute treatment has been revolution-
ized by the introduction of low–molecular weight
heparin preparations (LMWHs). Modalities that will
also be discussed include thrombolysis, thrombecto-
my, and inferior vena caval (IVC) interruption.
Adequate anticoagulation decreases the risk of
recurrent venous thromboembolism by approxi-
mately 80%, from 29% to 47% untreated to 5% to 7%
treated.5-8 During adequate anticoagulant therapy
(at least 5 days of heparin and 3 months of either
oral anticoagulants [international normalized ratio,
2.0-4.5], LMWH, or adjusted-dose subcutaneous
unfractionated heparin), the risk of fatal PE is very
low, 0.4% and 0.3% during and after treatment for
DVT and 1.5% and 0% during and after treatment
for PE. This was determined in a meta-analysis of 25
studies with confirmed objective diagnosis of DVT
and PE.9 Anticoagulation with heparin must be
achieved rapidly because it has been shown that, if
therapeutic levels are reached in the first 24 hours,
the recurrence rate is only 4% to 6% compared with
23% if it is not therapeutic in this time frame (level I
evidence).10 It has also been shown that continuous
intravenous unfractionated heparin is better than
intermittent subcutaneous standard heparin for
thromboembolism recurrence (level I evidence).11
After unfractionated heparin is begun, what are
the guidelines for its usage? Heparin for 5 days has
been compared with 10 days with no difference in
recurrent thrombosis (7.1% vs 7.0%, level I evi-
dence).12 Oral anticoagulants are begun with the
use of maintenance dosing, rather than loading dos-
ing, to decrease the risk of warfarin-induced skin
necrosis. Studies (all level I evidence) have evaluat-
ed the length of optimal oral anticoagulant therapy.
In a study that compared 6 weeks to 6 months of
warfarin (Coumadin), the recurrence rate was
18.1% as opposed to 9.5% in favor of the longer
treatment at 2-year follow-up.13 Another study
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compared 4 weeks to 3 months of treatment in
medical patients with 7.8% recurrence versus 4.0%
recurrence in favor of 3 months of treatment.14 A
third study suggested that oral anticoagulants
should be used for a longer rather than shorter peri-
od of time, especially in the presence of continuing
risk factors.15 Because no study has compared 3
months to 6 months, the usual recommendation is
for a period of oral anticoagulation after a first DVT
of 3 to 6 months, although the length should
depend on patient condition and history. For exam-
ple, with reversible or time-limited risk factors and a
first thromboembolic event, 3 to 6 months is rec-
ommended; although for an idiopathic cause and a
first event, 6 months is recommended.16 However,
even with the optimal treatment, DVT recurrences
should be expected. Symptomatic recurrent throm-
boembolism after a first episode of symptomatic
DVT in patients who were treated with heparin, 3
months of Coumadin, and stocking support was
17.5% after 2 years, 25% after 5 years, and 30% after
8 years (level I evidence).17 The risk was markedly
increased in the presence of Factor V Leiden.
Additionally, lifetime therapy is recommended for a
first thromboembolic event with malignancy (until
resolved), homozygous activated protein C (APC)
resistance, antiphospholipid antibody (until
resolved), and antithrombin III, protein C, or pro-
tein S deficiencies.16
A recent study that compared 3 months of anti-
coagulant therapy to a further 24 months has con-
cluded that, after a first episode of idiopathic venous
thromboembolism, patients should be treated with
anticoagulants longer than 3 months (level I evi-
dence).18 The rate of recurrent venous thromboem-
bolism was 27.4% per patient-year for the shorter
course, as opposed to 1.3% per patient-year for the
longer course of warfarin, with minimal increased
bleeding complications. The actual length of thera-
py recommended over and above 3 months is still to
be determined.
After a second episode of DVT, life-long oral
anticoagulant therapy is recommended. In patients
who experience a second episode of DVT, at 4-year
follow-up, recurrent DVT was seen in 20.7% in those
who received only 6 months of Coumadin therapy
and 2.6% in those on indefinite Coumadin therapy, a
relative eight-fold risk increase (level I evidence).19
However, the major bleeding risk increased four-fold
with no difference in mortality rate.
The most important complication of anticoagu-
lation therapy is bleeding. With the use of intra-
venous unfractionated heparin, the bleeding risk is
11% during the first 5 to 10 days.12 Adding in war-
farin, keeping the international normalized ratio at 2
to 3, the incidence of major bleeding is approxi-
mately 6% per year. Because of the bleeding risks
with unfractionated heparin, LMWHs were devised.
LMWH
LMWHs are derived from the lower molecu-
lar–weight range of heparin preparations by chem-
ical or enzymatic fragmentation. Unfractionated
heparin inhibits thrombin because it is large
enough to make a three-way complex between
thrombin, antithrombin, and itself. This complex
requires at least 18 saccharide units, and most
LMWHs are shorter than 18 saccharide units.
LMWHs thus have less antithrombin activity. For
inhibition of factor Xa, such a three-way complex
is not necessary, allowing LMWHs to exhibit more
antifactor Xa activity. In fact, each LMWH has its
own antifactor Xa to antifactor IIa activity ratio,
with most LMWH preparations having a ratio
between 2:1 to 4:1. Unfractionated heparin has a
ratio of 1:1.20
The advantages of LMWHs are many, and include
a decrease in bleeding potential, less antiplatelet activ-
ity, less risk for development of heparin-induced
thrombocytopenia, an improved pharmacokinetic
profile because of reduced nonspecific binding to
plasma proteins, less lipolysis, a half-life that is not
dose-dependent, more constant antifactor Xa inhibi-
tion, less interference with protein C activation and
appropriate platelet aggregation, less complement
activation, less risk of osteoporosis, and a lower level
of fibrin monomer production.20 Treatment with
LMWH does not need to be monitored with stan-
dard tests of global coagulation, because LMWH is
dosed on the basis of patient weight. LMWH is
administered by subcutaneous injection; its excretion
is primarily renal.
LMWHs have been recommended for both DVT
prophylaxis21 and treatment of venous thromboem-
bolism. Level I studies and meta-analyses have com-
pared LMWHs to unfractionated heparin for DVT
and PE treatment, and they have shown LMWH to be
at least as effective as, if not more effective than,
unfractionated heparin.22-28 There is a lower risk for
major bleeding, for recurrent thromboembolic events,
and even for death.29 For PE, LMWHs are equivalent
to and more convenient than standard heparin.30
LMWH therapy is dosed on the basis of weight and
does not need to be monitored by coagulation tests,
except possibly in special circumstances, such as in
renal failure. Because of the lack of monitoring neces-
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sarily and the use of intermittent subcutaneous injec-
tions, outpatient home treatment has become a reali-
ty. However, it must be remembered that there are
certain patients for whom outpatient treatment of
venous thromboembolism is not appropriate, such as
patients with phlegmasia, young patients with exten-
sive iliofemoral thrombosis, and patients with exten-
sive PE. These patients may need more aggressive
invasive therapy on an inpatient basis.
The economic impact of LMWH use rather than
unfractionated heparin for the treatment of venous
thromboembolism has been studied in level I and II
studies. Cost savings have ranged from greater than
$300,000 for 125 patients (or approximately
$2400/case) in the United States31 to approximate-
ly $4000 (US) per case in Canada.32 In a study that
involved centers in Europe, Australia and New
Zealand, a greater than 60% reduction in costs was
found,33 and once per day treatment with LMWH
(dalteparin) resulted in significant cost reductions in
a large multicenter Swedish study.34 Expanding indi-
cations to withholding LMWH therapy only to
those patients with massive PE, a high risk for major
or active bleeding, and phlegmasia and to patients
who are already hospitalized for other diseases has
resulted in more than 80% of patients becoming eli-
gible for outpatient home treatment.35 More than
90% of patients report high satisfaction with home
outpatient treatment.36
One of the areas of controversy involves the treat-
ment of calf vein thrombi. Approximately 20% of calf
thrombi extend into the popliteal vein, and extension
is associated with 40% to 50% rate of clinically
detectable PE. However, calf thrombi alone have
been associated with up to a 25% incidence of chron-
ic venous insufficiency 12 months after diagnosis and
an approximate 10% incidence of PE at presentation
(level V evidence).37 Thus most authorities today rec-
ommend full anticoagulation for isolated calf vein
thrombosis, especially in the presence of any other
risk factors. The ability to use outpatient LMWH will
likely end this controversy, and all calf-vein thrombi
will be treated with LMWH.
LMWH has also been studied in unstable angina,
as reviewed by Hirsh.20 LMWH has been found
superior to placebo and equivalent or superior to
unfractionated heparin concerning the endpoints of
death or myocardial infarction, without any increase
in major bleeding. The question remains whether
one preparation of LMWH will be found superior to
another or whether all preparations will share the
same advantages for the treatment of DVT, PE, and
unstable angina.
THROMBOLYSIS
The incidence of chronic venous insufficiency after
appropriate anticoagulant treatment for DVT has
been reported to be 23% after 2 years, 28% after 5
years, and 29% after 8 years.17 Because of this inci-
dence of valvular reflux resulting from DVT, the use of
thrombolytic agents to more rapidly clear venous
thrombosis has been advanced. With the use of duplex
ultrasound scanning, it has been found that sponta-
neous lysis time was 2.3- to 7.3-fold longer in reflux-
ing segments than in nonrefluxing segments (except
for the posterior tibial vein, level V evidence).38
Systemic thrombolysis in two small series (level II evi-
dence) revealed a decrease in the incidence of the
chronic venous insufficiency with streptokinase as
opposed to systemic heparin.39,40 However, results
depended on complete thrombolysis. This inability to
predict complete lysis combined with the risk of bleed-
ing led to thrombolysis falling out of favor. With the
use of intrathrombus urokinase for arterial thrombi, a
similar approach with urokinase directly into the
venous thrombi was attempted. Initial good results
(level V evidence)41 has led to a national thrombolysis
registry.42 In 287 of 473 patients who have undergone
follow-up, 312 urokinase infusions in 303 limbs have
been reported. Venous thrombi occurred in the
iliofemoral segment in 71% of cases, without the IVC
in 79% and including the IVC in 21%. Two thirds of
the patients had acute thrombosis, 16% chronically,
with combined acute and chronic in 19% of patients.
Approximately 31% of patients reported prior DVT,
and the favorite access site for urokinase infusion was
the popliteal vein (42% of cases). Complete thrombol-
ysis was achieved in 31% of cases, while partial lysis was
achieved in 52% of patients. The mean amount of
urokinase needed was 7.8 million units, for a mean
time of 53.4 hours. Predictors of successful lysis
included acute DVT and no prior history of DVT.
Complications included 11% major bleeding that
required blood products and 16% minor bleeding.
The mortality rate was 0.4%; the intracranial hemor-
rhage rate was at 0.2%, and the subdural hemorrhage
rate at 0.2%. Although total lysis was noted in only
31% of the entire series, in patients with acute
iliofemoral DVT, no previous symptoms, and the use
of the popliteal vein access site, total lysis was more fre-
quent in this group. Patency at 12 months was 79%
with complete lysis, 58% with more than 50% lysis, and
32% with less than 50% lysis. With complete lysis, no
valvular reflux was found in 72% of cases, although the
overall valvular reflux rate was 58% (level V evidence).
Thrombolytic therapy for PE remains controver-
sial. Although agents lyse thrombus effectively, patient
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mortality or recurrence rates have not been found to
be improved (level II evidence).43,44 Results are best if
patients are young, if the embolus is less than 48 hours
old, or if the embolus is large. Streptokinase, uroki-
nase, and tissue plasminogen activator45 have all been
used (level II evidence). All agents rapidly dissolve
clots, but by 7 days, the advantage for all three agents
disappears. The benefit for thrombolytic agents for PE
thus would appear to be in those patients who would
die of massive PE in the first hour after the PE occurs
(up to 10% of cases of PE).
VENOUS THROMBECTOMY
Iliofemoral venous thrombectomy has been
advocated in the setting of impending venous gan-
grene. This technique results in the mechanical clear-
ing of the venous circulation and may be combined
with a temporary arteriovenous fistula to increase
early patency. Thrombectomy is performed with a
Fogarty balloon catheter passed, most commonly,
from the femoral level, usually during patient Valsalva
maneuvers. The arteriovenous fistula is constructed
so that it can be taken down by angiographic, non-
surgical techniques and is made in the groin at the
femoral level. Completion venography in the operat-
ing room is recommended, because back-bleeding is
notoriously unreliable for the assessment of complete
thrombus clearance. Rethrombosis rates less than
20% have been reported (level II evidence).46 The
incidence of PE during the first week after thrombec-
tomy is equivalent to treatment with anticoagulation
only. The frequency of clinical success has been
reported between 42% and 93%.47 The largest series
of 77 legs with follow-up between 5 and 13 years
revealed the maintenance of patency but a steady
decline in valvular competence (level V evidence).48
In the only study for iliofemoral venous throm-
bosis that compared thrombectomy with anticoagu-
lation (n = 31 patients) versus anticoagulation alone
(n = 32 patients), the clinical outcome was better at
6 months (40% vs 7% asymptomatic patients),
iliofemoral vein patency was improved (76% vs
35%), and femoropopliteal patency was improved
with thrombectomy (52% vs 26%, level II evi-
dence).47 At 10 years, the number of patients avail-
able had fallen to 13 patients in the thrombectomy
group and 17 patients in the anticoagulation-alone
group. An improvement in patency in the
thrombectomy group was found (83% vs 41%), and
importantly, no popliteal reflux was found in only
43% of the anticoagulation alone group as opposed
to 78% in the thrombectomy plus anticoagulation
group.46 Thrombectomy failures included patients
with chronic iliac vein obstruction that created
rethrombosis and prior DVT that resulted in valvu-
lar reflux.
IVC INTERRUPTION
IVC interruption for venous thromboembolism is
appropriate if traditional anticoagulation fails, if anti-
coagulant agents are contraindicated, or if there is sig-
nificant bleeding associated with anticoagulation ther-
apy. Initially, direct IVC ligation resulted in significant
lower extremity venous complications and a high rate
of recurrent embolism. Thus initial intraoperative IVC
compartmentalization, clip devices, and eventually
intravascular venous devices that did not require
abdominal operative placement were developed.
These devices resulted in a decreased incidence of
venous stasis complications. The most effective device
currently available is the Greenfield vena cava filter, a
cone-shaped device. This cone-shape allows 85% of
the length of the device to contain clot and still main-
tain flow around its periphery, which allows natural
fibrinolysis to occur. Indications for IVC filtration
include venous thrombosis or PE in a patient with a
contraindication to anticoagulation therapy, a compli-
cation during anticoagulation therapy, recurrent PE in
the face of adequate anticoagulation therapy, chronic
PE with associated pulmonary hypertension and 
cor pulmonale, and immediately after pulmonary
embolectomy. Free-floating iliofemoral DVT may be
associated with a 60% incidence of PE despite ade-
quate anticoagulation therapy (level V evidence),49
while free-floating IVC thrombi demonstrate a 27%
incidence of PE despite adequate anticoagulation
(level V evidence).50 Bilateral free-floating femoral
thrombi have a 43% incidence of PE despite adequate
anticoagulation (level V evidence).51 These are all
additional indications for filter placement. In 642
patients reported in the largest experience in the liter-
ature with the Greenfield filter, a contraindication to
anticoagulation therapy was the most frequent reason
for filter insertion, followed by the failure of anticoag-
ulation therapy (level V evidence).52 Recurrent PE was
noted in only 4% of patients over a 20-year follow-up
period; the long-term IVC patency rate was 96% inde-
pendent of anticoagulation therapy, and venous ulcer-
ation was noted in only 3% of patients. No patient
with suprarenal filter placement (54 cases) was found
to have an occluded IVC or renal veins over the fol-
low-up period, which suggests that suprarenal filter
placement is safe if necessary, such as in pregnant
women or women of child-bearing age.
Percutaneous insertion versus direct surgical tech-
nique offers a number of advantages for the Greenfield
JOURNAL OF VASCULAR SURGERY
616 Wakefield March 2000
filter, which include decreased patient discomfort,
decreased time of insertion, and decreased cost. With
the use of a percutaneous approach with the original
24F carrier, the incidence of venous thrombosis at the
insertion site was reported as high as 41% (level V evi-
dence).53 In response to this problem, a titanium
Greenfield filter with modified hooks was developed,
which reduced the carrier to a size of 12F in a 14F
sheath. Outcomes for 173 patients revealed 97% suc-
cessful placement, a recurrent PE rate of only 3%, and
IVC occlusion in 1% (level V evidence).54 The venous
thrombosis rate at the insertion site was only 2%.
A recent study compared filter placement with
no filter placement in patients with proximal DVT
and also compared unfractionated heparin to
LMWH (level I evidence).55 A statistically signifi-
cant advantage was noted in the filter group at 12
days concerning symptomatic or asymptomatic PE,
although there were more recurrent DVTs at 2 years
in the filter group. Unfortunately, in this study, fil-
ters were not used with the usual indications as men-
tioned previously. Additionally, the association
between the filter presence and recurrent DVT is
unlikely, unless the filter catches a massive embolus
(leading to distal venous hypertension). This has
been rare in the 20-year follow-up of the Greenfield
filter.56 Thus this study has not lessened the benefit
of IVC filters in appropriate patients.
PULMONARY EMBOLECTOMY
Surgical approaches for PE are indicated in those
patients with massive embolism with hypotension
and who require large doses of vasopressors. These
are often patients in whom thrombolytic agents have
not been successful. Open pulmonary embolectomy
as practiced in the past is associated with a high mor-
bidity and mortality rate. Today, open pulmonary
embolectomy is limited to those patients who require
manual cardiac massage for hypotension or those
patients for whom catheter pulmonary embolectomy
fails. A catheter for the removal of pulmonary emboli
has been developed. Catheter pulmonary embolecto-
my is performed by insertion under local anesthesia
from either the jugular or common femoral vein.
This cup catheter is inserted through a transverse
venotomy, and the radiopaque catheter is then visu-
alized under fluoroscopy as it is guided into the right
side of the heart. The left main pulmonary artery is
most easily entered. The cup is juxtaposed up to the
embolus; syringe suction is used to aspirate the clot
into the cup, and the entire catheter and clot are
removed. Entry into the right pulmonary artery is
performed by deflecting the cup in that direction as
it reaches the superior edge of the heart. Multiple
retrievals may be necessary to remove enough
thrombus to improve pulmonary hemodynamics. In
a series of 46 patients treated with this device, emboli
were extracted in 76% of cases, and the 30-day sur-
vival was 70% (level V evidence).57 Embolectomy
was most successful for major PE and massive PE and
least helpful for chronic PE; successful embolectomy
predicted long-term survival. A recent addition to
pulmonary embolectomy is extended support with
the use of extracorporeal membrane oxygenation
(ECMO), to allow the lungs time to recover.
ALTERNATIVE ANTICOAGULANTS
Hirudin, a single-chain polypeptide, is obtained
from the saliva of leeches. It is composed of 65
amino acids, has a molecular weight of 8000 to
9000 daltons, and contains three disulfide bonds.
Hirudin has a short 15- to 30-minute half-life and
is excreted in the urine. It is a direct inhibitor of
thrombin and opposes all of thrombin’s actions,
which include conversion of fibrinogen to fibrin,
activation of factors V, VIII, and XIII to Va, VIIIa,
and XIIIa, and thrombin-induced platelet aggrega-
tion.58 Hirudin is more potent than heparin in
reducing platelet deposition and mural thrombosis.
Hirudin also prevents thrombus growth at high
and low blood-flow shear rates and can stop the
growth of thrombus, even in severe stenoses.
Unlike heparin, which can inhibit only free, circu-
lating unbound thrombin, hirudin and other direct
thrombin inhibitors act against both circulating
and clot-bound thrombin. The high incidence of
bleeding from hirudin, however, limits its useful-
ness clinically.59 The gene for hirudin was cloned in
1986, leading the way to the production of recom-
binant analogs such as Hirulog and Lepirudin.
Hirulog is much less potent than hirudin and
reveals a lack of toxicity and immunogenicity.59
Argatroban (a synthetic organic antithrombin) has
been found useful for the treatment of patients
with heparin-induced thrombocytopenia (HIT)
and heparin-induced thrombocytopenia and
thrombosis syndrome (HITS). Lepirudin has now
been approved by the US Food and Drug
Administration for use in HIT and HITS, with an
acceptable bleeding profile (level IV evidence).60
Ancrod is another alternative anticoagulant,
and its use during infrainguinal bypass operation
has been reported (level II evidence).61 This is a
thrombin-like enzyme derived from the Malayan
pit viper. Ancrod works by producing a controlled
decrease in fibrinogen levels by depleting fi-
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brinopeptide A from fibrinogen, but not fi-
brinopeptide B. The resulting fibrin monomers
stimulate the local production of tissue plasmino-
gen activator. Both of these actions lead to a state
of anticoagulation. However, the degree of fi-
brinogen decrease must be closely monitored to
prevent bleeding. Other agents are being devel-
oped against various aspects of the coagulation sys-
tem and include factor X inhibitors, activated pro-
tein C, and tissue factor pathway inhibitor. Platelet
aggregation is another target for inhibition.
Platelet aggregation can be inhibited by (1)
blocking cyclooxygenase, the first step in the con-
version of arachidonic acid to thromboxane A2; (2)
blocking thromboxane synthase, the enzyme that
leads to the production of thromboxane A2; (3)
blocking the thromboxane A2 receptor; (4)
increasing intraplatelet cyclic adenosine mono-
phosphate and cyclic guanosine monophosphate
levels, which inhibit the exposure of the platelet
GpIIb/IIIa receptor; or (5) directly blocking the
GpIIb/IIIa receptor. Aspirin and indomethacin
inhibit cyclooxygenase, which inhibits both prosta-
cyclin and thromboxane, although methylxan-
thines such as dipyridamole (Persantine) inhibit
phosphodiesterase, resulting in higher levels of
cyclic adenosine monophosphate. Ticlopidine
interferes with adenosine diphosphate–mediated
platelet aggregation. A ticlopidine analogue, clopi-
dogrel, was developed because of ticlopidine-asso-
ciated neutropenia. This thienopyridine com-
pound is not associated with the same degree of
neutropenia and has been reported to reduce the
composite endpoints of stroke, myocardial infarc-
tion, and death in patients with vascular disease.62
Direct inhibitors of GpIIb/IIIa were first devel-
oped as murine-derived monoclonal antibodies. The
compound abciximab (C7E3Fab; ReoPro), the first
agent to be available clinically, is a chimeric antibody
form of the monoclonal antibody directed at the
GpIIb/IIIa receptor.63 Its receptor binding is non-
specific, and it binds to other cell-surface integrins.
Agents in development include arginine-glycine-aspar-
tic acid (RGD) mimics that act as competitive antago-
nists to the GpIIb/IIIa receptor, including the cyclic
peptide eptifibatide (Integrilin), the parenteral non-
peptide mimetics lamifiban and tirofiban (Aggrastat),
oral nonpeptide mimetics xemilofiban, orbofiban, rox-
ifiban, sibrafiban, lefradafiban, and SB 214857, and
the parenteral and oral nonpeptide mimetic RPR-
109891 (Klerval).63 Studies with these agents have
involved coronary interventions (unstable angina or
myocardial infarction) in which these agents have been
reported to demonstrate advantage.62 The use of
these agents in peripheral vascular interventions and
venous thromboembolism await future study.
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